Xianming Deng

This inventor holds 30 USPTO granted patents and 5 published patent applications and 5 EPO patents. Top assignees: Dana-Farber-Cancer Institute Inc., Xiamen University, Scripps Research Institute. Active years: 2014-2025.

USPTO Granted Patents = 30 (Patent Applications = 5)

% Patents Active = 90.0

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 102(Granted Patents)

Location History:

Jamaica Plain, MA (US) (2014 - 2020)
Brookline, MA (US) (2015 - 2023)
Xiamen, CN (2021 - 2023)
Fujian, CN (2015 - 2024)

Company Filing History:

18 out of 1,264

Dana-Farber-Cancer Institute Inc.

Scripps Research Institute

patents

4. 2 out of 953

The United States Government as Represented by the Department of Veterans Affairs

University of Pittsburgh

patents

7. 2 out of 2

Xiamen Vivohealths Technology Co., Ltd.

patents

8. 1 out of 6

Anhui New Star Pharmaceutical Development Co., Ltd.

Hongyun Biotech Co., Ltd.

patent

12. 1 out of 408

Shanghai Jiao Tong University

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Imidazole Compounds

Myristate Inhibitors

Raf Kinase Inhibitors

STK19 Inhibitors

SPAK Kinase Inhibitors

Aza-Aromatic Compounds

Thienopyrimidine Compounds

Pyrimidine Compounds

Pyrimido-Diazepinone Compounds

Protein Kinase Inhibitors

Neuroprotective Agents

Drug Combinations

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410142 - Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof (2025-09-09),

2. 11932646 - Small molecule myristate inhibitors of Bcr-abl and methods of use (2024-03-19),

3. 11826365 - Type II raf kinase inhibitors (2023-11-28),

4. 11584722 - Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof (2023-02-21),

5. 11542240 - STK19 inhibitors for treatment of cancer (2023-01-03),

6. 11414379 - SPAK kinase inhibitors as neuroprotective agents (2022-08-16),

7. 11352354 - Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof (2022-06-07),

8. 11319322 - Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof (2022-05-03),

9. 11292787 - Five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof (2022-04-05),

10. 11254682 - Small molecule myristate inhibitors of Bcr-abl and methods of use (2022-02-22),

11. 11078213 - Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof (2021-08-03),

12. 10995061 - SPAK kinase inhibitors as neuroprotective agents (2021-05-04),

13. 10975092 - Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof (2021-04-13),

14. 10787461 - Pyrimido-diazepinone compounds and methods of treating disorders (2020-09-29),

15. 10787455 - Small molecule myristate inhibitors of BCR-ABL and methods of use (2020-09-29),

Title: Xianming Deng: Pioneering Cancer Research through Innovative Patents

Introduction

Xianming Deng, based in Fujian, China, is a prominent inventor with a remarkable portfolio of 29 patents. His work primarily focuses on innovative solutions in the field of oncology, particularly through the development of novel compounds aimed at combating cancerous diseases.

Latest Patents

Deng's most recent patents include groundbreaking developments such as "Small Molecule Myristate Inhibitors of Bcr-abl and Methods of Use." This patent introduces novel heteroaryl compounds that hold promise for the treatment of various cancers. Another significant patent is for "Type II Raf Kinase Inhibitors," which relates to new compounds capable of modulating B-Raf kinases, useful in treating a range of diseases and conditions.

Career Highlights

Throughout his career, Xianming Deng has worked with esteemed institutions such as Dana-Farber Cancer Institute and Xiamen University. These associations have allowed him to contribute significantly to cancer research and the advancement of therapeutic innovations.

Collaborations

Deng has collaborated with notable researchers including Nathanael Schiander Gray and Jianming Zhang. Their collective expertise has fostered advancements in cancer treatment, enhancing the potential efficacy of targeted therapies.

Conclusion

Xianming Deng's contributions to cancer research through his inventions are profound. His innovative approaches and collaborations with esteemed institutions and professionals underline his significant role in the landscape of modern medicine and ongoing efforts to improve therapeutic options for patients.